Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer

Seminars in Surgical Oncology

Volumn 20, Issue 2, 2001, Pages 134-146

  Bombardieri, Emilio ^a   Aliberti, Gianluca ^a   De Graaf, Celine ^b   Pauwels, Ernest ^b   Crippa, Flavio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gastrointestinal neoplasms; Positron emission tomography (PET), emission computed; Radionuclide imaging; Receptors, somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 5 HYDROXYTRYPTOPHAN; ANGIOPEPTIN; ARCITUMOAB; CARBON 11; CARCINOEMBRYONIC ANTIGEN; DEPREOTIDE TC 99M; DNA; IMMUNOGLOBULIN F(AB) FRAGMENT; INDIUM 111; IODINE 123; IODINE 131; LEVODOPA; METHIONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; PENTETREOTIDE; PENTETREOTIDE IN 111; POLYCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; SATUMAB PENDTIDE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THYMIDINE; UNCLASSIFIED DRUG; VAPREOTIDE; VAPREOTIDE TC 99M;

ADENOCARCINOMA; BILE DUCT CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; HUMAN; ISOTOPE LABELING; LIVER CANCER; NEUROENDOCRINE TUMOR; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH CANCER; WHOLE BODY SCINTISCANNING;

ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM STAGING; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034983693     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.1027     Document Type: Review

References (125)

1. Cancer of the digestive tract
2. Radionuclide imaging of neuroendocrine tumors: Biological basis and diagnostic results
3. Introduction to a revised clinico-pathological classification of neuroendocrine tumors of the gastroenteropancreatic tract
4. Radiopharmaceuticals in oncology
5. Tumor-seeking radiopharmaceuticals: Nature and mechanisms
6. The diagnostic role of radiolabelled antibodies
7. Radioimmunodetection in cancer identification
8. Clinical radioimmunodetection: The second decade
9. Monoclonal antibody pretargeting techniques for tumor localization: The avidin-biotin system
10. Bispecific monoclonal antibody-mediated targeting of an indium-111-labelled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response
11. 99mTc-labelling kit for antibody imaging
12. Immunoscintigraphy of colorectal adenocarcinoma: Results with site-specifically radiolabeled B72.3(111In-CYT-103)
13. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer
14. Preoperative clinical radioimmunodetection of pancreatic cancer by 111In-labeled chimeric monoclonal antibody ND2
15. Radiolabelled monoclonal antibodies against alpha-fetoprotein for in vivo localization of human hepatocellular carcinoma by immunotomoscintigraphy
16. Classification and nomenclature of somatostatin receptors
17. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide
18. General aspects of the biology and function of somatostatin
19. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneity
20. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
21. 1-1]-octreotide in humans
22. 99mTc-P829
23. The utility of a somatostatin type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules
24. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors
25. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging
26. Vasoactive intestinal peptide receptor scintigraphy
27. Iodine-123-4-amino-3-iodobenzylguanidine, a new sympatho-adrenal imaging agent: Comparison with iodine-131-metaiodobenzylguanidine
28. 123I-MIBG
29. Radiolabelled metaiodobenzylguanidine in the diagnosis of neural crest tumors
30. Neural crest tumors: Diagnosis
31. The role of PET imaging in clinical oncology. A current status report
32. Positron emission tomography with 18F-FDG
33. Limited value of fluorine-18 fluorodeoxyglucose PET for the imaging of neuroendocrine tumors
34. Neuroendocrine tumor imaging: Can FDG PET detect tumors with poor prognosis and aggressive behaviour?
35. Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow-up of carcinoid tumors
36. Pancreatic neuroendocrine tumors: Diagnosis with PET
37. 18F]fluoro-2-deoxy-D-glucose, radiopharmaceutical PET for oncology
38. 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography
39. Intratumoral distribution of fluorine-18- fluorodeoxiyglucose in vivo: High accumulation in macrophages and granulation tissues studied
40. Autoradiographic evaluation of intra-tumoral distribution of 2-deoxy-d-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma
41. The role of positron emission tomography in the detection of pancreatic disease
42. Imaging of the hepatocellular carcinoma using dynamic positron emission tomography with nitrogen-13-ammonia
43. PET radiopharmaceuticals: State-of-the-art and future prospects
44. Anticarcinoembryonic antigen immunoscintigraphy with a 99m Tc-Fag fragment (Immu4) in primary and recurrent colorectal cancer. A prospective study
45. Imaging of colorectal carcinoma with technetium 99m radiolabelled Fab fragment (Immu4) in primary and recurrent colorectal cancer: A prospective study
46. Klinische relevanz der immunszintigraphie mit 99mTc- marckierten AntiCea-Fab-Fragmenten in der nachsorge des kolorektalen karzinoms: Chirurgische resektatabilitas-beurtteilung aus der kombination mit konventioneller bildembung
47. Radioimmunodetection of colorectal carcinoma using technetium-99m labeled FAB fragments of the immuno-4 anti-carcinoembryonic antigen monoclonal antibody
48. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer
49. Use of radiolabeled antibodies to CEA for the detection and localization of divers cancers by external photoscanning
50. Radiolabeled antibody imaging in the management of colorectal cancer: Results of a multicenter clinical study
51. Clinical studies on the radioimmunodetection of tumors containing alpha-feto-protein
52. Imaging of primary metastatic liver cancer with I-131 monoclonal and polyclonal antibodies against alpha-fetoprotein
53. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit
54. The use of monoclonal antibodies (MAbs) and the development of an intraoperative hand-held probe for cancer detection
55. Intraoperative radioimmunodetection
56. Staging of colorectal cancer: Biology vs. morphology
57. Radioimmunoguided surgery using monoclonal antibody
58. Tc99-m labeled anti-CEA antibodies intraoperative diagnosis of colorectal cancer
59. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99-m-88BD59
60. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin
61. 3]-octreotide: The Rotterdam experience with more than 1000 patients
62. Somatostatin receptor scintigraphy in neuroendocrine gastro-entero-pancreatic tumors
63. SPECT improves accuracy of somatostatin receptors scintigraphy in abdominal carcinoids tumors
64. Somatostatin analogue scintigraphy in carcinoid tumors
65. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors
66. Use of radiolabelled somatostatin to localize islet cell tumors
67. Parallel in vivo and in vitro detection of functional somatostatine receptors in human endocrine pancreatic tumors. Consequences with regard to diagnosis, localisation and therapy
68. Results and potential of somatostatin receptors imaging in gastroenteropancreatic tract tumors
69. Cost-effectiveness analysis of somatostatin receptors scintigraphy
70. 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract
71. PET in oncology: Will it replace the other modalities?
72. Use of PET in neuroendocrine tumors in vivo applications and in vitro
73. FDG PET imaging of paragangliomas of the neck: Comparisons with MIBG SPECT
74. Increased accumulation of 2-deoxy-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma
75. Cost-effectiveness of PET imaging in clinical oncology
76. Colorectal cancer. Radiologic staging
77. Positron emission tomography for preoperative staging of colorectal carcinoma
78. Positron emission tomography to stage metastatic colorectal carcinoma to the liver
79. Staging recurrent metastatic colorectal carcinoma with PET
80. Recurrence of colorectal tumors: PET evaluation
81. Recurrent rectal cancer and scar: Differentiation with PET and MR imaging
82. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
83. Whole-body PET imaging with F-18-fluorodeoxyglucose in management of recurrent colorectal cancer
84. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice
85. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET
86. 18F]fluorodeoxyglucose in recurrent colorectal cancer
87. 18F]fluorodeoxyglucose in identifying operable colorectal cancer
88. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
89. Colorectal cancer
90. Positron emission tomography imaging: Diagnosis and management
91. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
92. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
93. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response fluorouracil
94. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization
95. Overexpression of glucose transporter-1 and increased FDG-uptake in pancreatic carcinoma
96. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography
97. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US
98. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation
99. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
100. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies
101. Detection of liver metastases from pancreatic cancer using FDG PET
102. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer
103. FDG-PET in the detection of pancreatic cancer liver metastases
104. Positron emission tomography imaging
105. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: An unsolved problem
106. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma
107. Hepatic metastases: Basic principles and implications for radiologist
108. Evaluation of benign vs malignant hepatic lesions with positron emission tomography
109. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
110. Accurate detection of liver metastases in patients with primary malignancies using PET-FDG imaging
111. The influence of blood glucose levels on [18F] fluorodeoxyglucose (FDG) uptake in cancer: A PET study in liver metastases from colorectal carcinomas
112. Quantitative evaluation of glucose utilization in liver metastases, parametric imaging of FDG uptake with PET
113. Evaluation of liver tumors using 18F-fluorodeoxyglucose PET: Characterization of the tumor and assessment of the effect of the treatment
114. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET
115. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy
116. Analysis of glucose metabolism in patients with esophageal cancer by PET: Estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose
117. Positron emission tomography for staging of esophageal and gastroesophageal malignancy
118. Role of positron emission tomography in staging esophageal cancer
119. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma
120. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
121. 18F fluoredeoxyglucose positron emission tomography
122. The role of cost effectiveness analysis in health care evaluation
123. The need of cost-effectiveness evaluation when using high-cost equipment in national health services
124. Clinical trials of cost effectiveness in technology evaluation
125. Health technology assessment